MCID: LYM012
MIFTS: 49

Lymphoplasmacytic Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma 11 14 36 75 33
Waldenström Macroglobulinaemia Without Mention of Remission 33
Malignant Lymphoma - Lymphoplasmacytic 71
Waldenström Macroglobulinaemia 33
Waldenstrom Macroglobulinemia 71
Idiopathic Macroglobulinaemia 33
Primary Macroglobulinaemia 33

Classifications:



External Ids:

Disease Ontology 11 DOID:0050747
ICD11 33 2058944823
UMLS 71 C0024419 C0334633

Summaries for Lymphoplasmacytic Lymphoma

Disease Ontology: 11 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

MalaCards based summary: Lymphoplasmacytic Lymphoma, also known as waldenström macroglobulinaemia without mention of remission, is related to macroglobulinemia and waldenstroem's macroglobulinemia. An important gene associated with Lymphoplasmacytic Lymphoma is PAX5 (Paired Box 5), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Cyclophosphamide and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia: 75 Waldenström macroglobulinemia (/ˈvɑːldənstrɛm ˌmækroʊˌɡlɒbjələˈniːmiə/) is a type of cancer affecting... more...

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 macroglobulinemia 31.4 SDC1 PAX5 MYD88 CXCR4 BTK BCL2
2 waldenstroem's macroglobulinemia 31.3 SDC1 PAX5 MYOM2 MYD88 MIR9-1 IGHV4-38-2
3 burkitt lymphoma 31.1 PAX5 MME CD19 BCL6 BCL2 B2M
4 lymphoma, hodgkin, classic 30.9 PAX5 MIR9-1 BCL6 BCL2
5 amyloidosis 30.8 MYOM2 MME CCND1 B2M
6 heavy chain disease 30.6 MYOM2 MYD88 IGHV4-38-2 CD79A
7 cryoglobulinemia 30.6 CD79A CD5 BCL2
8 pancytopenia 30.5 MME CD5 CD22 CD19
9 lymphoproliferative syndrome 30.5 CD5 BCL6 BCL2
10 lymphoma 30.5 PAX5 MYD88 CXCR4 CD5 CD38 CD19
11 immunoglobulin light chain amyloidosis 30.4 SDC1 MYOM2 IGHV4-38-2 CD38 B2M
12 hematologic cancer 30.4 PAX5 MIR9-1 CXCR4 BCL2
13 agammaglobulinemia 30.4 CXCR4 CD79B CD79A CD19 BTK
14 leukemia, chronic lymphocytic 2 30.4 CD5 CD38 BCL2
15 agammaglobulinemia, x-linked 30.3 CD79B CD79A CD19 BTK
16 mediastinal cancer 30.3 PAX5 CD79A CD5
17 gamma heavy chain disease 30.3 SDC1 PAX5 IGHV4-38-2 CD38 CD19
18 chromosome 13q14 deletion syndrome 30.2 IGHV4-38-2 CD5 CD38
19 anemia, autoimmune hemolytic 30.2 IGHV4-38-2 CD5 CD38 CD19 BTK
20 primary central nervous system lymphoma 30.2 PAX5 MYD88 BCL6
21 intravascular large b-cell lymphoma 30.2 BCL6 BCL2
22 prostate lymphoma 30.1 MME CD79A CD5 BCL6
23 deficiency anemia 30.0 MME CD5 CD38 CD19 B2M
24 bone lymphoma 30.0 PAX5 MME CD79A CD5 BCL6 BCL2
25 follicular lymphoma 30.0 PAX5 MME CXCR4 CD5 CCND1 BCL6
26 b-cell lymphoma 29.9 PAX5 MYD88 MME CXCR4 CD79B CD5
27 leukemia, chronic myeloid 29.9 MIR9-1 CD38 CD19 CCND1 BCL2
28 monoclonal gammopathy of uncertain significance 29.9 SDC1 MYOM2 MYD88 IGHV4-38-2 CD38 CD19
29 smoldering myeloma 29.8 SDC1 MYOM2 IGHV4-38-2 CD38 CD19 B2M
30 plasmacytoma 29.8 PAX5 CD79B CD79A CD5 CD38 CCND1
31 nodal marginal zone lymphoma 29.7 MME IGHV4-38-2 CD79A CD5 BCL6 BCL2
32 gastric lymphoma 29.7 MME IGHV4-38-2 CD79A CD5 BCL6 BCL2
33 plasma cell leukemia 29.7 SDC1 MYOM2 IGHV4-38-2 CD38 CCND1 B2M
34 plasma cell neoplasm 29.6 SDC1 PAX5 MYOM2 MYD88 IGHV4-38-2 CD79A
35 lymphatic system disease 29.5 MME MIR9-1 IGHV4-38-2 CD5 CD19 BCL6
36 diffuse large b-cell lymphoma 29.5 PAX5 MYD88 MME MIR9-1 IGHV4-38-2 CD79B
37 gastrointestinal lymphoma 29.5 MME IGHV4-38-2 CD79A CD5 CCND1 BCL6
38 composite lymphoma 29.4 PAX5 MME IGHV4-38-2 CD79A CD5 CD22
39 richter's syndrome 29.4 PAX5 IGHV4-38-2 CD79B CD5 CD38 CD22
40 splenic marginal zone lymphoma 29.3 PAX5 MYD88 MME IGHV4-38-2 CD79B CD79A
41 peripheral nervous system disease 29.2 MYOM2 MME MIR9-1 CXCR4 CD19 CCND1
42 marginal zone b-cell lymphoma 29.1 SDC1 PAX5 MYD88 MME IGHV4-38-2 CD79B
43 myeloma, multiple 29.0 SDC1 PAX5 MYOM2 MYD88 MIR9-1 CXCR4
44 chronic lymphocytic leukemia/small lymphocytic lymphoma 28.9 PAX5 MME IGHV4-38-2 CD79B CD79A CD5
45 leukemia, acute lymphoblastic 28.8 PAX5 MME MIR9-1 IGHV4-38-2 CXCR4 CD5
46 lymphoma, mucosa-associated lymphoid type 28.6 SDC1 PAX5 MYD88 MME IGHV4-38-2 CD79B
47 leukemia, chronic lymphocytic 28.4 SDC1 PAX5 MYD88 MME MIR9-1 IGHV4-38-2
48 mature b-cell neoplasm 28.3 SDC1 PAX5 MYOM2 MME MIR9-1 IGHV4-38-2
49 leukemia, acute myeloid 28.2 SDC1 PAX5 MME MIR9-1 IGHV4-38-2 CXCR4
50 lymphoma, non-hodgkin, familial 28.2 SDC1 PAX5 MYD88 MME MIR9-1 IGHV4-38-2

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:



Diseases related to Lymphoplasmacytic Lymphoma

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 B2M BCL2 BCL6 BTK CARD11 CCND1
2 cellular MP:0005384 10.13 B2M BCL2 BCL6 BTK CARD11 CCND1
3 immune system MP:0005387 10.09 B2M BCL2 BCL6 BTK CARD11 CCND1
4 neoplasm MP:0002006 10.07 B2M BCL2 BTK CCND1 CD19 CD79A
5 hematopoietic system MP:0005397 9.86 B2M BCL2 BCL6 BTK CARD11 CCND1
6 integument MP:0010771 9.44 B2M BCL2 BCL6 BTK CARD11 CCND1

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
4
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
5
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Etoposide Approved Phase 4 33419-42-0 36462
8
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
9 Anti-Bacterial Agents Phase 4
10 Anti-Infective Agents Phase 4
11 Immunosuppressive Agents Phase 4
12 Angiogenesis Inhibitors Phase 4
13
Etoposide phosphate Phase 4 16760419
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
16
Chlorambucil Approved Phase 3 305-03-3 2708
17
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
18
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
19
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
20
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
21 Cyclosporins Phase 3
22 Antifungal Agents Phase 3
23 Alkylating Agents Phase 3
24 Antineoplastic Agents, Alkylating Phase 3
25 Antineoplastic Agents, Hormonal Phase 3
26 Hormones Phase 3
27 Hormone Antagonists Phase 3
28 Antiemetics Phase 3
29 glucocorticoids Phase 3
30 Anti-Inflammatory Agents Phase 3
31 Gastrointestinal Agents Phase 3
32 HIV Protease Inhibitors Phase 3
33
protease inhibitors Phase 3
34 BB 1101 Phase 3
35 Cc-486 Phase 2, Phase 3
36
Belimumab Approved Phase 2 356547-88-1
37
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
38
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
39
Ichthammol Approved Phase 1, Phase 2 8029-68-3
40
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
41
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704
42
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
43
Adenosine Approved, Investigational Phase 2 58-61-7 60961
44
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693
45
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
46
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
47
Atorvastatin Approved Phase 2 134523-00-5 60823
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
49
Iron Approved Phase 2 7439-89-6 29936
50
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381

Interventional clinical trials:

(show top 50) (show all 330)
# Name Status NCT ID Phase Drugs
1 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
2 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
3 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
4 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Active, not recruiting NCT04042376 Phase 4 Ibrutinib
5 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
6 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
7 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
8 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
9 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
10 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Completed NCT03053440 Phase 3 BGB-3111;Ibrutinib
11 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
12 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
13 Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1) Recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
14 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
15 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
16 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 Ibrutinib
17 A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements Suspended NCT04799275 Phase 2, Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
18 A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma Unknown status NCT03335098 Phase 2 Bortezomib
19 A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia. Unknown status NCT03679455 Phase 2 Obinutuzumab 25 MG/ML
20 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
21 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
22 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
23 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
24 Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC) Completed NCT00723099 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
25 Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00142181 Phase 2 Campath-1H
26 Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00020800 Phase 2 fludarabine phosphate
27 A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies Completed NCT03010358 Phase 1, Phase 2 Entospletinib
28 Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Completed NCT00142116 Phase 2 Thalidomide;Rituximab
29 Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas Completed NCT01076543 Phase 1, Phase 2 Lenalidomide;Temsirolimus
30 Phase II Study of Velcade in Waldenstrom's Macroglobulinemia Completed NCT00142129 Phase 2 Bortezomib (Velcade)
31 A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies Completed NCT01474681 Phase 1, Phase 2
32 A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphomas Refractory to Rituximab and Alkylating Agents Completed NCT01282424 Phase 2 Idelalisib
33 A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults Completed NCT01314014 Phase 2 Imexon
34 A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II) Completed NCT01381692 Phase 1, Phase 2 Bortezomib;Dexamethasone;Temsirolimus
35 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
36 Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia Completed NCT02677324 Phase 2 ABT199
37 A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB
38 A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial Completed NCT00789776 Phase 1, Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
39 A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma Completed NCT00711828 Phase 2 Bortezomib;Cyclophosphamide;Dexamethasone
40 A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma Completed NCT00438880 Phase 1, Phase 2 Agatolimod Sodium
41 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
42 A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma Completed NCT03364231 Phase 2 Umbralisib
43 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
44 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
45 UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia Completed NCT00083707 Phase 2 Thalidomide
46 A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01109069 Phase 2 PCI-32765
47 Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma Completed NCT00244855 Phase 2 dexamethasone
48 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
49 Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial Completed NCT00096161 Phase 2 Cyclosporine;Mycophenolate Mofetil;Pentostatin
50 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone

Search NIH Clinical Center for Lymphoplasmacytic Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Cyclophosphamide
Ibrutinib
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoplasmacytic Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoplasmacytic Lymphoma

Anatomical Context for Lymphoplasmacytic Lymphoma

Organs/tissues related to Lymphoplasmacytic Lymphoma:

MalaCards : B Cells, Bone Marrow, T Cells, Myeloid, Lymph Node, Liver, Bone

Publications for Lymphoplasmacytic Lymphoma

Articles related to Lymphoplasmacytic Lymphoma:

(show top 50) (show all 892)
# Title Authors PMID Year
1
Diagnosing Multiple Myeloma and Related Disorders. 62
36270842 2023
2
A fatal case of a CD5-positive lymphoplasmacytic lymphoma with associated AL-type amyloidosis. 62
35596646 2022
3
Bing-Neel Syndrome Successfully Treated with Tirabrutinib. 62
35569989 2022
4
Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenström macroglobulinaemia including BTKi failures: A real-world analysis. 62
36467794 2022
5
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. 62
36435884 2022
6
Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. 62
36441109 2022
7
Anemia - an initial manifestation of Bing-Neel syndrome: A case report. 62
36401435 2022
8
Baseline 18 F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. 62
35961637 2022
9
Plasma cell neoplasms and related entities-evolution in diagnosis and classification. 62
36414803 2022
10
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. 62
36400069 2022
11
Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis. 62
36467836 2022
12
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms. 62
36244464 2022
13
Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma. 62
36266677 2022
14
Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. 62
36247137 2022
15
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. 62
36210485 2022
16
Protein-losing enteropathy in association with gastrointestinal IgM deposition in Waldenström macroglobulinaemia. 62
35796502 2022
17
A Rare Case of Laryngeal Non-IgM Lymphoplasmacytic Lymphoma. 62
36159343 2022
18
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. 62
35849723 2022
19
Overexpression of interleukin-20 correlates with favourable prognosis in diffuse large B-cell lymphoma. 62
36175183 2022
20
Research progress on epigenetics of small B-cell lymphoma. 62
35334078 2022
21
Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma. 62
35932039 2022
22
The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. 62
35954476 2022
23
Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study 62
34619856 2022
24
Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib. 62
35110483 2022
25
Cutaneous lymphoplasmacytic lymphoma with MYD88 L265P mutation, bone marrow involvement, and paraproteinaemia. 62
34895930 2022
26
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. 62
35339405 2022
27
New treatment strategies for Waldenström macroglobulinemia. 62
36125957 2022
28
Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group. 62
35956064 2022
29
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis. 62
35937468 2022
30
Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM. 62
35537114 2022
31
Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis. 62
35276022 2022
32
Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. 62
35339566 2022
33
Acute kidney injury due to direct infiltration by lymphoplasmacytic lymphoma secreting IgG paraproteins: A case report. 62
35713455 2022
34
Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. 62
35877223 2022
35
Russell Body Esophagitis: A Possible Indication to Screen for Hematologic Malignancy. 62
35770181 2022
36
Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia. 62
35067139 2022
37
A challenging case of lymphoproliferative disease in a cat. 62
35181934 2022
38
Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study. 62
35029297 2022
39
Central nervous system manifestations of systemic haematological malignancies and key differentials. 62
35164931 2022
40
A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. 62
34802044 2022
41
A rare case of type II cryoglobulinemic vasculitis with renal and pulmonary involvement in a patient with underlying lymphoplasmacytic lymphoma. 62
35383893 2022
42
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. 62
34699012 2022
43
Concomitant lymphoplasmacytic lymphoma, multiple myeloma, and amyloidosis: A diagnostic and therapeutic challenge. 62
35474975 2022
44
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. 62
35454017 2022
45
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. 62
35020191 2022
46
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. 62
35267584 2022
47
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. 62
35139644 2022
48
Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. 62
34959252 2022
49
Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy. 62
35449638 2022
50
Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia). 62
35257101 2022

Variations for Lymphoplasmacytic Lymphoma

Expression for Lymphoplasmacytic Lymphoma

Search GEO for disease gene expression data for Lymphoplasmacytic Lymphoma.

Pathways for Lymphoplasmacytic Lymphoma

Pathways related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 B2M BCL2 BCL6 BTK CARD11 CCND1
2
Show member pathways
13.62 B2M BTK CCND1 CD19 CD79A CD79B
3
Show member pathways
13.33 MYD88 CD79B CD79A CD19 CCND1 BTK
4
Show member pathways
13.27 MYD88 CD79B CD79A CD22 CD19 CARD11
5
Show member pathways
12.18 CD79B CD79A CD22 CD19 BTK BCL6
6
Show member pathways
12.08 CD22 CD19 BTK BCL6
7 11.84 PAX5 MYD88 CXCR4 CD79A CD38 CD19
8 11.79 CCND1 BCL6 BCL2
9 11.76 CCND1 BCL6 BCL2
10 11.74 CCND1 BCL6 BCL2
11 11.73 CD79B CD79A BTK
12 11.7 SDC1 CD79A CD19
13 11.62 SDC1 MME CD79B CD79A CD5 CD38
14 11.6 PAX5 CCND1 BCL2
15 11.59 PAX5 CXCR4 CD79A CD22 CD19 BCL6
16 11.56 MYD88 CXCR4 BCL2
17 11.55 CXCR4 CCND1 BCL2
18 11.52 MME CD38 CD19
19 11.51 BCL6 BTK CARD11 CD19 CD22 CD79A
20
Show member pathways
11.31 CD79B CD79A CD22 CD19 BTK

GO Terms for Lymphoplasmacytic Lymphoma

Cellular components related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.65 MME CD79A CD19 CARD11 BTK
2 external side of plasma membrane GO:0009897 9.55 SDC1 IGHV4-38-2 CXCR4 CD79B CD79A CD5
3 B cell receptor complex GO:0019815 9.46 CD79B CD79A

Biological processes related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 I-kappaB kinase/NF-kappaB signaling GO:0007249 10 MYD88 CARD11 BTK
2 B cell proliferation GO:0042100 9.96 CD79A CD38 CARD11 BCL6 BCL2
3 immune system process GO:0002376 9.92 B2M BCL6 BTK CARD11 CD19 CD79A
4 response to glucocorticoid GO:0051384 9.91 SDC1 CCND1 BCL2
5 B cell activation GO:0042113 9.91 CD79A CD22 BTK
6 regulation of immune response GO:0050776 9.88 CD22 CARD11 BCL6
7 positive regulation of B cell proliferation GO:0030890 9.85 BCL2 BCL6 BTK CARD11 CD38
8 response to organic cyclic compound GO:0014070 9.8 MYD88 CXCR4 CCND1 BCL2
9 response to organic substance GO:0010033 9.67 SDC1 CCND1 BTK
10 B cell differentiation GO:0030183 9.65 PAX5 CD79B CD79A CARD11 BCL6 BCL2
11 regulation of programmed cell death GO:0043067 9.63 CXCR4 BCL2
12 negative regulation of leukocyte proliferation GO:0070664 9.54 BTK BCL6
13 B cell receptor signaling pathway GO:0050853 9.44 IGHV4-38-2 CD79B CD79A CD38 CD19 BTK

Sources for Lymphoplasmacytic Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....